drugset / Trial / NCT06016634
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Phase 2
Recruiting
30 enrolled
University of California, Davis
Doris Duke Charitable Foundation · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Timeline
- Start
- 2026-03-09
- Primary completion
- 2027-09
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | 70 mg | Oral |